TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma (TheraSphere)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00906984|
Recruitment Status : Recruiting
First Posted : May 21, 2009
Last Update Posted : April 19, 2021
The purpose of this protocol is to provide TheraSphere treatment for patients with liver cancer who cannot be treated by surgery. The effect on the tumor and any side effects of TheraSphere treatment will be examined. This study will provide supervised and limited access to TheraSphere treatment at University California Irvine Medical Center.
TheraSphere is a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. When Y-90 is incorporated into very tiny glass beads (TheraSphere), it can be injected to the liver through blood vessels supplying the liver. This allows a large dose of radiation to be delivered to the tumor with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue. The radiation from TheraSphere is contained within the body and becomes minimally active within 7 days after treatment due to physical decay. The glass beads remain in the body, but do not cause any health problems. TheraSphere has been approved for use in the treatment of liver cancer in the United States by the Food and Drug Administration on a limited basis.
|Condition or disease||Intervention/treatment||Phase|
|Hepatocellular Carcinoma Liver Cancer Liver Neoplasm Primary Liver Cancer||Device: TheraSphere||Not Applicable|
This protocol provides TheraSphere treatment for patients with liver cancer who cannot be treated by surgery. Patients with hepatocellular carcinoma will be evaluated for eligibility for this treatment with the following: physical examination, medical history, blood tests requiring approximately 2 tablespoons of blood, EKG, CT or MR of chest to examine lungs, CT or magnetic resonance (MR) of abdomen to evaluate liver, stomach and intestines, and bone scan to rule out spread of disease to bones. If eligible on initial screening, patients will proceed to a second stage of screening, including an hepatic angiogram to confirm treatment can be provided safely and to highlight the blood vessels supplying the liver, and a nuclear medicine study (Tc-99m MAA scan) to display the blood flow to the lungs, stomach and intestines.
When it is determined treatment can be delivered safely, patients will receive TheraSphere via the hepatic artery through blood vessels supplying the liver on an outpatient basis.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||130 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Humanitarian Device Exemption Treatment Protocol of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma|
|Actual Study Start Date :||May 8, 2002|
|Estimated Primary Completion Date :||October 21, 2021|
|Estimated Study Completion Date :||October 21, 2021|
TheraSphere® treatment will be performed in the outpatient setting. The effect on the tumor and any side effects of TheraSphere® HUD treatment will be examined. This is not a research study and there are no comparison or experimental treatments being used. Within 14 days of initial treatment, reverification of eligibility will be confirmed. If review of eligibility indicates an uncorrectable risk of flow to the gastrointestinal organs or risk of shunting to the lungs, treatment will not be administered. In this event, the patient will receive alternative treatment (chemoembolization) or no treatment. If the patient remains eligible, TheraSphere® will be administered within 14 days. All patients will be evaluated at 30 days post-treatment to assess clinical experience and adverse effects. Subsequently, patient status will be followed via communication with the referring oncologist to determine disease status and survival. Survival surveillance will continue up to 24 months.
- The protocol allows for prospective collection of data. There is no randomization to an alternative form of therapy. However, we measure tumor response after treatment based on CT scans and tumor markers. [ Time Frame: Every 3-6 months ]
- Evaluate for side effects [ Time Frame: Every 1-2 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00906984
|Contact: Chao Family Comprehensive Cancer Center University of California, Irvine Medical Center||(877) 827-8839||UCstudy@uci.edu|
|United States, California|
|Chao Family Comprehensive Cancer Center||Recruiting|
|Orange, California, United States, 92868|
|Principal Investigator: David K Imagawa, MD, PhD|
|Principal Investigator:||Nadine Abi-Jaoudeh, MD||University of California, Irvine|